BCDA News and Press, BioCardia Inc. From 08/04/21

SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, announced today that Chief Executive Officer, Peter Altman, will participate in a fir...

BioCardia (BCDA) announces that the Japan Patent Office has granted Patent No: 6887216 related to the company's imaging system for targeting cardiac therapies.The patent titled  titled, "Target Site Selection, Entry, and Update With Automatic Remote Image Annotation" will expir...

SAN CARLOS, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Japan Patent Office has granted Patent No: 6887...

BioCardia (BCDA) announces that the independent Data Safety Monitoring Board ((DSMB)) has recommended that the company continue with its late-stage heart failure trial as designed.The DSMB's recommendation comes after it completed a prespecified data review for the Phase III pivotal ...

SAN CARLOS, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring B...

SAN CARLOS, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its CardiAMP Cell Therapy Hea...

SAN CARLOS, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the European patent office has issued a...

BCDA has candidate therapies that could potentially be curative of very prevalent heart diseases. The therapies have advanced to Phase 3 trials. Despite this, the company trades at a fully diluted market cap of only $105M. For further details see: Why I've Taken A Small ...

On the conclusion of the 2021 Russell indexes annual reconstitution, regenerative biologic therapies developer BioCardia (BCDA) will join the Russell Microcap Index, effective June 28, 2021 after market opens. BioCardia CEO commented, "BioCardia’s inclusion in the Russel...

SAN CARLOS, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today announced it is to join the Russell Microcap ® Index. This milestone w...